Star Equity Holdings, Inc. (STRR)
USD 2.0
(-0.99%)
USD 2.0
(-0.99%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.14 Million USD | -67.54% |
| 2022 | 3.52 Million USD | 6.91% |
| 2021 | 3.29 Million USD | -80.86% |
| 2020 | 17.23 Million USD | -14.29% |
| 2019 | 20.11 Million USD | 111.69% |
| 2018 | 9.5 Million USD | -51.28% |
| 2017 | 19.5 Million USD | 21.34% |
| 2016 | 16.07 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 99 Thousand USD | -73.1% |
| 2005 | 368 Thousand USD | -79.02% |
| 2004 | 1.75 Million USD | -62.86% |
| 2003 | 4.72 Million USD | -18.1% |
| 2002 | 5.76 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.02 Million USD | 0.0% |
| 2024 Q2 | 8.27 Million USD | 0.0% |
| 2023 Q4 | 1.14 Million USD | -8.62% |
| 2023 FY | 1.14 Million USD | -67.54% |
| 2023 Q1 | 3.04 Million USD | -13.55% |
| 2023 Q3 | 1.25 Million USD | -8.67% |
| 2023 Q2 | 1.37 Million USD | -55.0% |
| 2022 Q4 | 3.52 Million USD | -10.07% |
| 2022 Q3 | 3.92 Million USD | -6.6% |
| 2022 Q1 | 4.63 Million USD | 40.5% |
| 2022 FY | 3.52 Million USD | 6.91% |
| 2022 Q2 | 4.19 Million USD | -9.41% |
| 2021 FY | 3.29 Million USD | -80.86% |
| 2021 Q2 | 2.15 Million USD | -43.15% |
| 2021 Q3 | 2.7 Million USD | 25.29% |
| 2021 Q4 | 3.29 Million USD | 22.19% |
| 2021 Q1 | 3.79 Million USD | -78.01% |
| 2020 Q1 | 22.17 Million USD | 10.28% |
| 2020 Q4 | 17.23 Million USD | -12.84% |
| 2020 Q3 | 19.77 Million USD | -10.71% |
| 2020 Q2 | 22.14 Million USD | -0.14% |
| 2020 FY | 17.23 Million USD | -14.29% |
| 2019 FY | 20.11 Million USD | 111.69% |
| 2019 Q1 | 15.08 Million USD | 58.75% |
| 2019 Q2 | 17.98 Million USD | 19.28% |
| 2019 Q3 | 20.57 Million USD | 14.37% |
| 2019 Q4 | 20.11 Million USD | -2.25% |
| 2018 Q3 | 13.59 Million USD | 8.74% |
| 2018 Q1 | 13 Million USD | -33.33% |
| 2018 Q4 | 9.5 Million USD | -30.11% |
| 2018 Q2 | 12.5 Million USD | -3.85% |
| 2018 FY | 9.5 Million USD | -51.28% |
| 2017 Q3 | 18.5 Million USD | 5.85% |
| 2017 FY | 19.5 Million USD | 21.34% |
| 2017 Q2 | 17.47 Million USD | 18.15% |
| 2017 Q4 | 19.5 Million USD | 5.41% |
| 2017 Q1 | 14.79 Million USD | -7.95% |
| 2016 Q3 | 17.34 Million USD | -9.88% |
| 2016 FY | 16.07 Million USD | 0.0% |
| 2016 Q4 | 16.07 Million USD | -7.32% |
| 2016 Q2 | 19.24 Million USD | -26.36% |
| 2016 Q1 | 26.12 Million USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q1 | 75 Thousand USD | 0.0% |
| 2008 Q4 | - USD | -100.0% |
| 2008 Q3 | 62 Thousand USD | -8.82% |
| 2008 FY | - USD | 0.0% |
| 2008 Q2 | 68 Thousand USD | -9.33% |
| 2007 FY | - USD | -100.0% |
| 2007 Q4 | - USD | -100.0% |
| 2007 Q3 | 2000.00 USD | -60.0% |
| 2007 Q2 | 5000.00 USD | -87.8% |
| 2007 Q1 | 41 Thousand USD | -58.59% |
| 2006 FY | 99 Thousand USD | -73.1% |
| 2006 Q2 | 229 Thousand USD | -23.15% |
| 2006 Q3 | 162 Thousand USD | -29.26% |
| 2006 Q1 | 298 Thousand USD | -19.02% |
| 2006 Q4 | 99 Thousand USD | -38.89% |
| 2005 Q2 | 643 Thousand USD | -26.6% |
| 2005 FY | 368 Thousand USD | -79.02% |
| 2005 Q1 | 876 Thousand USD | -50.06% |
| 2005 Q3 | 480 Thousand USD | -25.35% |
| 2005 Q4 | 368 Thousand USD | -23.33% |
| 2004 Q1 | 4.21 Million USD | 0.0% |
| 2004 Q2 | 3.38 Million USD | -19.49% |
| 2004 Q3 | 2.68 Million USD | -20.77% |
| 2004 FY | 1.75 Million USD | -62.86% |
| 2004 Q4 | 1.75 Million USD | -34.68% |
| 2003 FY | 4.72 Million USD | -18.1% |
| 2002 FY | 5.76 Million USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aspira Women's Health Inc. | 1.43 Million USD | 19.93% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | -2.372% |
| Intelligent Bio Solutions Inc. | 81.32 Thousand USD | -1307.948% |
| Standard BioTools Inc. | 3.98 Million USD | 71.253% |
| Inotiv, Inc. | 399.4 Million USD | 99.713% |
| Prenetics Global Limited | 867.21 Thousand USD | -32.032% |
| Neuronetics, Inc. | 59.28 Million USD | 98.069% |
| Castle Biosciences, Inc. | 14.19 Million USD | 91.935% |
| Psychemedics Corporation | 945 Thousand USD | -21.164% |
| RadNet, Inc. | 812.06 Million USD | 99.859% |
| Exact Sciences Corporation | 2.47 Billion USD | 99.954% |
| IDEXX Laboratories, Inc. | 622.88 Million USD | 99.816% |
| iSpecimen Inc. | 29.13 Thousand USD | -3830.656% |
| OpGen, Inc. | 2.02 Million USD | 43.362% |
| Exagen Inc. | 19.23 Million USD | 94.046% |
| Bionano Genomics, Inc. | 7.17 Million USD | 84.042% |
| CareDx, Inc | 28.27 Million USD | 95.951% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 79.17 Million USD | 98.554% |
| Guardant Health, Inc. | 1.13 Billion USD | 99.9% |
| Biodesix, Inc. | 35.22 Million USD | 96.749% |
| BioNexus Gene Lab Corp. | 98.76 Thousand USD | -1059.341% |
| Precipio, Inc. | 106 Thousand USD | -980.189% |
| Natera, Inc. | 282.94 Million USD | 99.595% |
| Fulgent Genetics, Inc. | 10.11 Million USD | 88.676% |
| Sera Prognostics, Inc. | 840 Thousand USD | -36.31% |
| 23andMe Holding Co. | 67.84 Million USD | 98.312% |
| OPKO Health, Inc. | 222.03 Million USD | 99.484% |
| Personalis, Inc. | 1.23 Million USD | 7.212% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 62.752% |
| Applied DNA Sciences, Inc. | 739.16 Thousand USD | -54.905% |
| T2 Biosystems, Inc. | 6.59 Million USD | 82.646% |
| Neogen Corporation | 888.39 Million USD | 99.871% |
| Myriad Genetics, Inc. | 130.9 Million USD | 99.125% |
| ICON Public Limited Company | 3.66 Billion USD | 99.969% |
| NeoGenomics, Inc. | 606.06 Million USD | 99.811% |
| Star Equity Holdings, Inc. | 1.14 Million USD | 0.0% |
| MDxHealth SA | 35.56 Million USD | 96.78% |
| Prenetics Global Limited | 867.21 Thousand USD | -32.032% |
| Illumina, Inc. | 1.48 Billion USD | 99.923% |
| DarioHealth Corp. | 24.59 Million USD | 95.344% |
| ENDRA Life Sciences Inc. | 192.06 Thousand USD | -496.162% |
| Medpace Holdings, Inc. | 142.12 Million USD | 99.194% |
| Mainz Biomed B.V. | 2.19 Million USD | 47.857% |
| Trinity Biotech plc | 54.65 Million USD | 97.905% |
| Sotera Health Company | 2.22 Billion USD | 99.949% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | -2.372% |